Misplaced Pages

Revision as of 12:33, 12 December 2008

Myalgic encephalomyelitis/chronic fatigue syndrome
Specialty	Neurology, rheumatology

Chronic fatigue syndrome (CFS) is the most common name given to a poorly understood, variably debilitating disorder or disorders of uncertain causation.

Symptoms of CFS include widespread muscle and joint pain, cognitive difficulties, chronic, often severe mental and physical exhaustion and other characteristic symptoms in a previously healthy and active person. Fatigue is a common symptom in many illnesses, but CFS is a multi-systemic disease and is relatively rare by comparison. Diagnosis requires a number of features, the most common being severe mental and physical exhaustion which is "unrelieved by rest" and is worsened by exertion. Most diagnostic criteria require that symptoms must be present for at least six months, and all state the symptoms must not be caused by other medical conditions. CFS patients may report additional symptoms, including muscle weakness, cognitive dysfunction, hypersensitivity, orthostatic intolerance, digestive disturbances, depression, poor immune response, and cardiac and respiratory problems. It is unclear if these symptoms represent co-morbid conditions or are produced by an underlying etiology of CFS. Full resolution occurs in only 5-10% of cases.

CFS is thought to have an incidence of 4 adults per 1,000 in the United States. For unknown reasons, CFS occurs more often in women than men, and in people in their 40s and 50s. The illness is estimated to be less prevalent among children and adolescents, but studies are contradictory as to the degree. There is no medical test which is widely accepted to be diagnostic of CFS. It remains a diagnosis of exclusion based largely on patient history and symptomatic criteria, although a number of tests can aid diagnosis.

Whereas there is agreement on the genuine threat to health, happiness, and productivity posed by CFS, various physicians groups, researchers, and patient activists promote different nomenclature, diagnostic criteria, etiologic hypotheses, and treatments, resulting in controversy about many aspects of the disorder. The name CFS itself is controversial, as advocacy groups as well as some experts feel it trivializes the illness and have supported efforts to change it. Many alternative names for chronic fatigue syndrome exist.

Signs and symptoms

Onset

The majority of CFS cases start suddenly, usually accompanied by a "flu-like illness" which is more likely to occur in winter, while a significant proportion of cases begin within several months of severe adverse stress. Because some people have a case of flu-like or other respiratory infection such as bronchitis, from which they seem never to fully recover, an Australian research group states that post-viral fatigue syndrome could be a subset of CFS. The accurate prevalence and exact roles of infection and stress in the development of CFS however are currently unknown.

Symptoms

The United States Centers for Disease Control (CDC) has established a definition of CFS that is the most commonly used in research and clinical applications. According to the CDC, CFS involves:

1. Fatigue, unexplained, persisting (lasting six months or longer), "not due to ongoing exertion," and not substantially reduced by rest. The person must have experienced a significant reduction in activity levels.

2. Four or more of the following symptoms:

• Impaired memory or concentration
• Post-exertional malaise, where physical or mental exertions bring on "extreme, prolonged exhaustion and sickness"
• Unrefreshing sleep
• Muscle pain (myalgia)
• Pain in multiple joints (arthralgia)
• Headaches of a new kind or greater severity
• Sore throat, frequent or recurring
• Tender lymph nodes (cervical or axillary)

When symptoms can be due to other conditions, the diagnosis of CFS is excluded. The CDC specifically refers to several problems with symptoms resembling those of CFS: "mononucleosis, Lyme disease, lupus, multiple sclerosis, fibromyalgia, primary sleep disorders, severe obesity and major depressive disorders. Medications can also cause side effects that mimic the symptoms of CFS."

Activity levels

Patients report critical reductions in levels of physical activity and are as impaired as persons whose fatigue can be explained by another medical or a psychiatric condition. According to the CDC, studies show that the degree of disability or functional impairment in CFS patients is comparable to that caused by well-known, severe medical conditions, such as multiple sclerosis, late-stage AIDS, lupus, rheumatoid arthritis, heart disease, end-stage renal disease, chronic obstructive pulmonary disease (COPD), and the effects of chemotherapy. The severity of symptoms and disability is the same in both genders, and chronic pain is strongly disabling in CFS patients, but despite a common diagnosis the functional capacity of CFS patients varies greatly. While some patients are able to lead a relatively normal life, others are totally bed-bound and unable to care for themselves. A systematic review found that in a synthesis of studies, 42% of patients were employed, 54% were unemployed, 64% reported CFS-related work limitations, 55% were on disability benefits or temporary sick leave, and 19% worked full-time.

Mechanism

The mechanisms and pathogenesis of chronic fatigue syndrome are unknown, but are the subjects of many research studies, including physiological and epidemiological studies. Hypotheses being researched include viral infection, hypothalamic-pituitary-adrenal axis abnormalities (though it is unclear if this is a cause, or consequence, of CFS), immune dysfunction, mental and psychosocial factors causing or contributing towards CFS. Because of social prejudices assuming that psychological disorders are not biological or "real", many patients object to the idea that the CFS is a mental disorder. Other hypotheses include oxidative stress and genetic predisposition. Both "neuroticism and introversion" may predispose people to getting CFS.

Exposure to chemicals, infectious agents, stress, and other insults in early life have been suggested as a component of later-life CFS. Another hypothesis is that a virus or another infectious agent might provoke an abnormal immune response in some people becomes a chronic, rather than an acute response. Abnormal expressions have also been documented for 88 human genes in CFS patients; the genes were associated with blood diseases and functioning, the immune system, cancer, cell death and infection. Abnormal biological responses to exercise have also been detected, relating to oxidative stress and immune function.

The central nervous system is important in CFS. Research has been reported on a "Hyperserotonergic state and hypoactivity of the hypothalamic-pituitary-adrenal axis (HPA axis)" in CFS. Genetic factors may be the basis for some of these changes. A 2008 study of gene polymorphisms indicates genetic predisposition possibly resulting in enhanced activity of serotonin. Another report says that low cortisol levels can be responsible: "hypocortisolaemia might sensitize the hypothalamic-pituitary-adrenal axis to development of persistent central fatigue after stress." Some researchers conclude that the involvement of the nervous and immune systems involvements are intertwined.

CFS may be perpetuated when patients fixate on a physical cause of illness and on sensations, and when they implement avoidance behaviors. Lack of support or reinforcement of illness behavior from social networks can also delay recovery, as can conflict with doctors who insist on psychological causes over a patient's objections.

Classification

There are no diagnostic tests or physical signs for CFS, so testing is used to rule out other potential causes for symptoms. The most widely used clinical and research description of CFS is the CDC definition published in 1994 (details given above). The 1994 CDC definition, also called the Fukuda definition after the first author on the report, was based on the Holmes or CDC 1988 scoring system. The 1994 criteria require the presence of only four symptoms beyond fatigue, where the 1988 criteria require six to eight.

Other notable definitions include

• The Oxford criteria (1991)

• The 2003 Canadian case definition for ME/CFS was developed "in an attempt to exclude psychiatric cases." This definition requires presence of symptoms from at least one category of autonomic, neuroendocrine, or immune symptoms. Doctors with the National Health Service in the UK are discouraged from using this case definition, since requiring the presence of these signs could exclude patients, and the criteria "have not been evaluated for research purposes."

Using different case definitions may influence the types of patients selected. Some authors suggest that subtypes of patients may exist. Clinical practice guidelines, with the aim of improving diagnosis, management, and treatment, are generally based on case descriptions. Guidelines are usually produced at national or international levels by medical associations or governmental bodies after evidence is examined and usually include summarized consensus statements. An example of a CFS guideline for the National Health Service in England and Wales, produced in 2007 by the National Institute for Health and Clinical Excellence (NICE).

Treatment

Many patients do not fully recover from CFS, even with treatment. Some management strategies are suggested to reduce the consequences of having CFS. Medications, other medical treatments, and complementary and alternative medicine are considered, but currently the only known treatments with "scientifically proven value in randomized controlled trials" are the behavioral therapies cognitive behavioral therapy (CBT) and graded exercise therapy (GET). A systematic review published in 2006 in the Journal of the Royal Society of Medicine and a 2006 review in The Lancet found that CBT and GET were the only two known "interventions found to be beneficial," confirming earlier conclusions.

Psychological therapy

The currently most effective known treatment for CFS is cognitive behavioral therapy (CBT), a form of psychological therapy. CBT tries to help patients understand their individual symptoms and beliefs and develop strategies to improve day-to-day functioning. The therapy may have special value for treating medically unexplained symptoms (MUS) like CFS according to Deary et al. who write, "a broadly conceptualized cognitive behavioural model of MUS suggests a novel and plausible mechanism of symptom generation and has heuristic value."

A Cochrane Review meta-analysis of 15 randomized, controlled cognitive behavioral therapy trials with 1043 participants concluded that CBT was an effective treatment. Comparing CBT with "usual care," four reviewed studies showed that CBT was more effective (40% vs 26%). In three studies, CBT worked better than other types of psychological therapies (48% vs 27%). The effects may diminish after a course of therapy is completed; the reviewers write that "the evidence base at follow-up is limited to a small group of studies with inconsistent findings" and encourage further studies.

Different trials of CBT use different measures of outcome, and some studies report higher success rates (as high as 70% and 73%) than those reviewed by Cochrane. One study suggests that CBT could facilitate full recovery in some patients, with 69% of the treated patients no longer meeting the CDC criteria for CFS. In a review in The Lancet, Dutch researchers state that while CBT is not necessarily a cure for CFS, in some studies it results in improvements in about 70% of patients. They stress that, with the current understanding of the biological nature of the brain, a psychological CFS model does not preclude neurobiological components. The authors of the Australian 2002 clinical practice guidelines state that unwarranted speculation about psychogenesis based on the outcome of CBT trials, should be avoided.

Whether or not CBT works for individual patients depends on many factors. A treatment can only work if patients agree to it, and Cochrane observes an "understandable ambivalence of many CFS patients towards a psychological treatment for symptoms that are experienced as physical." Patient characteristics predicting a poor outcome of CBT include "membership of a self-help group, receipt of a sickness benefit, low sense of control, a strong focus on symptoms, and a pervasively passive activity pattern."

Exercise therapy

Over half of CFS patients studied experience improvements when using graded exercise therapy (GET), a form of physical therapy. Meta-analysis of multiple randomized, controlled trials of exercise therapy of patients diagnosed with CFS shows improvements in fatigue symptoms over controls. Some patient organizations dispute the results of the exercise therapy trials.

Other

Other treatments of CFS have been proposed but not much is known about how effective they are. Medications thought to have promise in alleviating stress-related disorders include antidepressant and immunomodulatory agents such as staphypan Berna, lactic acid bacteria, kuibitang and intravenous immunoglobulin. CFS patients are less susceptible to placebo effects than predicted, and have a low placebo response compared to patients with other diseases. CFS is associated with chemical sensitivity, and some patients often respond to a fraction of a therapeutic dose that is normal for other conditions. Adaptive pacing is another proposed therapy.

Prognosis

Recovery

A systematic review of 14 studies of the outcome of untreated people with CFS found that "the median full recovery rate was 5% (range 0-31%) and the median proportion of patients who improved during follow-up was 39.5% (range 8-63%). Return to work at follow-up ranged from 8 to 30% in the three studies that considered this outcome." .... "In five studies, a worsening of symptoms during the period of follow-up was reported in between 5 and 20% of patients." According to the CDC, delays in diagnosis and treatment can reduce the chance of improvement.

Deaths

CFS is unlikely to increase the risk of an early death. A systematic review of 14 studies of the outcome of CFS reported 8 deaths, but none were considered directly attributable to CFS. To date there have been two studies directly addressing life expectancy in CFS. In a preliminary 2006 study of CFS self-help group members, it was reported that CFS patients were likely to die at a younger than average age for cancer, heart failure, and suicide. However, a much larger study of 641 CDC criteria diagnosed patients with CFS, who were followed up for a mean of 9 years, showed no excess risk of dying from any cause. A notable death of a CFS patient was Sophia Mirza.

Epidemiology

Due to the multiple definition of CFS, estimates of its prevalence vary widely. Studies in the United States have previously found between 75 and 420 cases of CFS for every 100,000 adults. The CDC states that more than 1 million Americans have CFS and approximately 80% of the cases are undiagnosed. All ethnic and racial groups appear susceptible to the illness, and lower income groups are slightly more likely to develop CFS. More women than men get CFS — between 60 and 85% of cases are women; however, there is some indication that the prevalence among men is underreported. The illness is reported to occur more frequently in people between the ages of 40 and 59. Blood relatives of people who have CFS appear to be more predisposed. However, there is no evidence that CFS is contagious. Caretakers, partners and others who are not blood relatives but are in close and prolonged contact with persons with CFS do not develop CFS any more frequently than the rest of the population.

Disease associations

Some diseases show a considerable overlap with CFS. Thyroid disorders, anemia, and diabetes are a few of the diseases that must be ruled out if the patient presents with appropriate symptoms.

People with fibromyalgia (FM, or fibromyalgia syndrome, FMS) have muscle pain and sleep disturbances. Fatigue and muscle pain occurs frequently in the initial phase of various hereditary muscle disorders and in several autoimmune, endocrine and metabolic syndromes; and are frequently labelled as CFS or fibromyalgia in the absence of obvious biochemical/metabolic abnormalities and neurological symptoms. Those with multiple chemical sensitivity (MCS) are sensitive to chemicals and have sleep disturbances. Many veterans with Gulf War syndrome (GWS) have symptoms almost identical to CFS. One study found several parallels when relating the symptoms of Post-polio syndrome with CFS, and postulates a possible common pathophysiology for the illnesses.

Although post-Lyme syndrome and CFS share many features/symptoms, a study found that patients of the former experience more cognitive impairment and the patients of the latter experience more flu-like symptoms.

One review (2006) found that there was a lack of literature to establish the discriminant validity of undifferentiated somatoform disorder from CFS. The author stated that there is a need for proponents of chronic fatigue syndrome to distinguish it from undifferentiated somatoform disorder. The author also mentioned that the experience of fatigue as exclusively physical and not mental is captured by the definition of somatoform disorder but not CFS. Hysterical diagnoses are not merely diagnoses of exclusion but require criteria to be met on the positive grounds of both primary and secondary gain. Primary depression can be excluded in the differential diagnosis due to the absence of anhedonia and la belle indifference, the variability (lability) of mood, and the presence of sensory phenomena and somatic signs such as ataxia, myclonus and most importantly, exercise intolerance with paresis, malaise and general deterioration. Feeling depressed is also a commonplace reaction to the losses caused by chronic illness which can in some cases become a comorbid situational depression.

Co-morbidity

Many CFS patients will also have, or appear to have, other medical problems or related diagnoses. Co-morbid fibromyalgia is common, where only patients with fibromyalgia show abnormal pain responses. Fibromyalgia occurs in a large percentage of CFS patients between onset and the second year, and some researchers suggest fibromyalgia and CFS are related. Similarly, multiple chemical sensitivity (MCS) is reported by many CFS patients, and it is speculated that these similar conditions may be related by some underlying mechanism, such as elevated nitric oxide/peroxynitrite. As previously mentioned, many CFS sufferers also experience symptoms of irritable bowel syndrome, temporomandibular joint pain, headache including migraines, and other forms of myalgia. Clinical depression and anxiety are also commonly co-morbid. Compared with the non-fatigued population, male CFS patients are more likely to experience chronic pelvic pain syndrome (CP/CPPS), and female CFS patients are also more likely to experience chronic pelvic pain. CFS is significantly more common in women with endometriosis compared with women in the general USA population.

History

A major outbreak of a condition similar to CFS in 1934 at the Los Angeles County Hospital affected all or most of its nurses and doctors. It was referred to as atypical poliomyelitis, and was generally believed to be a form of polio.

The outbreak that gave rise to the name Royal Free disease or benign myalgic encephalomyelitis (see History of chronic fatigue syndrome) occurred at London's Royal Free Hospital in 1955, affecting mostly the hospital staff, and formed the basis of descriptions by Achenson, Ramsay, and others.

Benign myalgic encephalomyelitis was first classified into the International Classification of Diseases in 1969 under Diseases of the nervous system.

The name chronic fatigue syndrome has been attributed to the 1988 article, "Chronic fatigue syndrome: a working case definition", (the Holmes definition). This research case definition was published after US Centers for Disease Control epidemiologists examined patients at the Lake Tahoe outbreak.

In 2006 the CDC estimated there were more than 1 million cases of CFS in the US and commenced a public awareness program.

Society and culture

Social issues

Many patients report that a chronic fatigue syndrome diagnosis carries a considerable stigma, and has frequently been viewed as malingering, hypochondria, phobia, "wanting attention" or "yuppie flu". As there is no objective test for the condition at this time, it has been argued that it is easy to invent or feign CFS-like symptoms for financial, social, or emotional benefits. CFS sufferers argue in turn that the perceived "benefits" are hardly as generous as some may believe, and that CFS patients would greatly prefer to be healthy and independent. The Australian 2002 clinical practice guidelines for CFS state that "In the absence of evidence of malingering, speculative judgements about unconscious motivation should be avoided; the psychoanalytic concept of 'secondary gain' has been misused in medicolegal settings and does not rest on a solid empirical base."

A study found that CFS patients endure a heavy psychosocial burden. 2,338 respondents of a survey by a UK patient organization highlights that those with the worst symptoms often receive the least support from health and social services. A study found that CFS patients receive worse social support than disease-free cancer patients or healthy controls, which may perpetuate fatigue severity and functional impairment in CFS. A survey by the Thymes Trust found that children with CFS often state that they struggle for recognition of their needs and/or they feel bullied by medical and educational professionals. The ambiguity of the status of CFS as a medical condition may cause higher perceived stigma. A study suggests that while there are no gender differences in CFS symptoms, men and women have different perceptions of their illness and are treated differently by the medical profession. Anxiety and depression often result from the emotional, social and financial crises caused by CFS. While few studies have been made, it is believed that CFS patients are at a high risk of suicide.

Doctor-patient relations

Some in the medical community did not at first recognize CFS as a real condition, nor was there agreement on its prevalence. There has been much disagreement over proposed causes, diagnosis, and treatment of the illness. The context of contested causation may affect the lives of the individuals diagnosed with CFS, affecting the patient-doctor relationship, the doctor's confidence in their ability to diagnose and treat, ability to share issues and control in diagnosis with the patient, and raise problematic issues of reparation, compensation, and blame. The etiology is unknown and a major divide exists over whether funding for research and treatment should focus on physiological, psychological or psychosocial aspects of CFS. The division is especially great between patient groups and psychological and psychosocial treatment advocates in Great Britain. Sufferers describe the struggle for healthcare and legitimacy due to bureaucratic denial of the condition because of its lack of a known etiology. Disagreements over how the condition is dealt with by health care systems has resulted in an expensive and prolonged conflict for all involved.

Naming

The nomenclature of the condition(s) has been challenging, since consensus is lacking within the clinical, research, and patient communities regarding its defining features and causes. Authorities on the illness look upon the condition as a central nervous system, metabolic, (post-)infectious, cardiovascular, immune system or psychiatric disorder, and consider the possibility that it is not a single homogenous disorder (with a range of possible clinical presentations), but a group of several distinct disorders with many clinical characteristics in common.

Over time and in different countries many names have been associated with the condition(s). Aside from CFS, some other names used include Akureyri disease, benign myalgic encephalomyelitis, chronic fatigue immune dysfunction syndrome, chronic infectious mononucleosis, epidemic myalgic encephalomyelitis, epidemic neuromyasthenia, Iceland disease, myalgic encephalomyelitis (ME, particularly in the United Kingdom, Canada, New Zealand and Australia), myalgic encephalitis, myalgic encephalopathy, post-viral fatigue syndrome, raphe nucleus encephalopathy, Royal Free disease, Tapanui flu and yuppie flu (now considered pejorative). Many patients particularly prefer what they feel is a more "medical-sounding" term, such as "chronic fatigue immune dysfunction syndrome" (CFIDS) or "myalgic encephalomyelitis" (ME), believing the name "chronic fatigue syndrome" trivializes the condition and prevents it from being seen as a serious health problem.

Researchers question the accuracy of the term "myalgic encephalomyelitis" since there is "no recognized pathology in muscles and in the central nervous system." For this reason, in 1999 the Royal Colleges of Physicians, Psychiatrists, and General Practitioners in the United Kingdom called for doctors to stop using the diagnosis. The Royal Colleges later bowed to protests by patient groups and endorsed using ME along with CFS. A recent review states an article from 1959 suggests ME could be a distinct condition, a current view of some patient groups, but CFS and ME are usually used as synonyms.

References

1. Ranjith G (2005). "Epidemiology of chronic fatigue syndrome". Occup Med (Lond). 55 (1): 13–29. doi:10.1093/occmed/kqi012. PMID 15699086.
2. ^ Wyller VB (2007). "The chronic fatigue syndrome--an update". Acta neurologica Scandinavica. Supplementum. 187: 7–14. doi:10.1111/j.1600-0404.2007.00840.x. PMID 17419822.
3. ^ Afari N, Buchwald D (2003). "Chronic fatigue syndrome: a review". Am J Psychiatr. 160 (2): 221–36. doi:10.1176/appi.ajp.160.2.221. PMID 12562565.
4. ^ "Chronic Fatigue Syndrome Basic Facts" (htm). Centers for Disease Control and Prevention. May 9, 2006. Retrieved 2008-02-07.
5. Jason LA; et al. (1999). "A community-based study of chronic fatigue syndrome". Arch. Intern. Med. 159 (18): 2129–37. doi:10.1001/archinte.159.18.2129. PMID 10527290. {{cite journal}}: Explicit use of et al. in: |author= (help)
6. Gallagher AM, Thomas JM, Hamilton WT, White PD (2004). "Incidence of fatigue symptoms and diagnoses presenting in UK primary care from 1990 to 2001". J R Soc Med. 97 (12): 571–5. doi:10.1258/jrsm.97.12.571. PMID 15574853.{{cite journal}}: CS1 maint: multiple names: authors list (link)
7. ^ "Chronic Fatigue Syndrome Who's at risk?". Centers for Disease Control and Prevention. March 10, 2006. Retrieved 2008-02-07.
8. ^ Ross SD, Estok RP, Frame D, Stone LR, Ludensky V, Levine CB (2004). "Disability and chronic fatigue syndrome: a focus on function". Arch Intern Med. 164 (10): 1098–107. doi:10.1001/archinte.164.10.1098. PMID 15159267.{{cite journal}}: CS1 maint: multiple names: authors list (link)
9. ^ Salit IE (1997). "Precipitating factors for the chronic fatigue syndrome". J Psychiatr Res. 31 (1): 59–65. doi:10.1016/S0022-3956(96)00050-7. PMID 9201648.
10. Jason LA, Taylor RR, Carrico AW (2001). "A community-based study of seasonal variation in the onset of chronic fatigue syndrome and idiopathic chronic fatigue". Chronobiol Int. 18 (2): 315–9. doi:10.1081/CBI-100103194. PMID 11379670.{{cite journal}}: CS1 maint: multiple names: authors list (link)
11. Zhang QW, Natelson BH, Ottenweller JE, Servatius RJ, Nelson JJ, De Luca J, Tiersky L, Lange G (2000). "Chronic fatigue syndrome beginning suddenly occurs seasonally over the year". Chronobiol Int. 17 (1): 95–9. doi:10.1081/CBI-100101035. PMID 10672437.{{cite journal}}: CS1 maint: multiple names: authors list (link)
12. Hatcher S, House A (2003). "Life events, difficulties and dilemmas in the onset of chronic fatigue syndrome: a case-control study" (PDF). Psychol Med. 33 (7): 1185–92. doi:10.1017/S0033291703008274. PMID 14580073.
13. Theorell T, Blomkvist V, Lindh G, Evengard B. "Critical life events, infections, and symptoms during the year preceding chronic fatigue syndrome (CFS): an examination of CFS patients and subjects with a nonspecific life crisis". Psychosom Med. 61 (3): 304–10. PMID 10367610.{{cite journal}}: CS1 maint: multiple names: authors list (link)
14. Hickie I, Davenport T, Wakefield D; et al. (2006). "Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study". BMJ. 333 (7568): 575. doi:10.1136/bmj.38933.585764.AE. PMID 16950834. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
15. ^ CDC website "Chronic Fatigue Syndrome"
16. McCully KK, Sisto SA, Natelson BH (1996). "Use of exercise for treatment of chronic fatigue syndrome". Sports Med. 21 (1): 35–48. doi:10.2165/00007256-199621010-00004. PMID 8771284.{{cite journal}}: CS1 maint: multiple names: authors list (link)
17. Solomon L, Nisenbaum R, Reyes M, Papanicolaou DA, Reeves WC (2003). "Functional status of persons with chronic fatigue syndrome in the Wichita, Kansas, population". Health Qual Life Outcomes. 1 (1): 48–58. doi:10.1186/1477-7525-1-48. PMID 14577835.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link) PMC 239865
18. Press Conference: The Chronic Fatigue and Immune Dysfunction Syndrome Association of America and The Centers For Disease Control and Prevention Press Conference at The National Press Club to Launch a Chronic Fatigue Syndrome Awareness Campaign - November 3 2006
19. "Chronic Fatigue Syndrome: Clinical Course". CDC.
20. Ho-Yen DO, McNamara I (1991). "General practitioners' experience of the chronic fatigue syndrome". Br J Gen Pract. 41 (349): 324–6. PMID 1777276.
21. Meeus M, Nijs J, Meirleir KD (2007). "Chronic musculoskeletal pain in patients with the chronic fatigue syndrome: A systematic review". Eur J Pain. 11 (4): 377–386. doi:10.1016/j.ejpain.2006.06.005. PMID 16843021.{{cite journal}}: CS1 maint: multiple names: authors list (link)
22. Vanness JM, Snell CR, Strayer DR, Dempsey L 4th, Stevens SR (2003). "Subclassifying chronic fatigue syndrome through exercise testing". Med Sci Sports Exerc. 35 (6): 908–13. doi:10.1249/01.MSS.0000069510.58763.E8. PMID 12783037.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: numeric names: authors list (link)
23. Vercoulen JH, Swanink CM, Galama JM; et al. (1998). "The persistence of fatigue in chronic fatigue syndrome and multiple sclerosis: development of a model". J Psychosom Res. 45 (6): 507–17. doi:10.1016/S0022-3999(98)00023-3. PMID 9859853. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
24. Cho HJ, Hotopf M, Wessely S (2005). "The placebo response in the treatment of chronic fatigue syndrome: a systematic fatigue syndrome (CFS) or myalgic encephalomyelitis (ME)". Psychosom Med. 67 (2): 301–13. PMID 15784798. {{cite journal}}: Text "locatreview and meta-analysis." ignored (help)CS1 maint: multiple names: authors list (link)
25. Sanders P, Korf J (2007). "Neuroaetiology of chronic fatigue syndrome: An overview". World J Biol Psychiatry: 1–7. doi:10.1080/15622970701310971. PMID 17853290. {{cite journal}}: Cite has empty unknown parameters: |1= and |unused_data= (help); Text "1B69BA326FFE69C3F0A8F227DF8201D0" ignored (help)
26. ^ Prins JB, van der Meer JW, Bleijenberg G (2006). "Chronic fatigue syndrome". Lancet. 367 (9507): 346–55. PMID 16443043.{{cite journal}}: CS1 maint: multiple names: authors list (link)
27. Dietert RR, Dietert JM (2008). "Possible role for early-life immune insult including developmental immunotoxicity in chronic fatigue syndrome (CFS) or myalgic encephalomyelitis (ME)". Toxicology. 247 (1): 61–72. doi:10.1016/j.tox.2008.01.022. PMID 18336982. {{cite journal}}: Unknown parameter |month= ignored (help)
28. Appel S, Chapman J, Shoenfeld Y (2007). "Infection and vaccination in chronic fatigue syndrome: myth or reality?". Autoimmunity. 40 (1): 48–53. doi:10.1080/08916930701197273. PMID 17364497.{{cite journal}}: CS1 maint: multiple names: authors list (link)
29. Kerr JR (2008). "Gene profiling of patients with chronic fatigue syndrome/myalgic encephalomyelitis". Curr Rheumatol Rep. 10 (6): 482–91. PMID 19007540.
30. Nijs J, Meeus M, De Meirleir K (2006). "Chronic musculoskeletal pain in chronic fatigue syndrome: recent developments and therapeutic implications". Man Ther. 11 (3): 187–91. PMID 16781183.{{cite journal}}: CS1 maint: multiple names: authors list (link)
31. Thambirajah AA, Sleigh K, Stiver HG, Chow AW (2008). "Differential heat shock protein responses to strenuous standardized exercise in chronic fatigue syndrome patients and matched healthy controls". Clin Invest Med. 31 (6): 319–27. PMID 19032901.{{cite journal}}: CS1 maint: multiple names: authors list (link)
32. Snell CR, Vanness JM, Strayer DR, Stevens SR (2005). "Exercise capacity and immune function in male and female patients with chronic fatigue syndrome (CFS)". In Vivo. 19 (2): 387–90. PMID 15796202.{{cite journal}}: CS1 maint: multiple names: authors list (link)
33. Cho HJ, Skowera A, Cleare A, Wessely S (2006). "Chronic fatigue syndrome: an update focusing on phenomenology and pathophysiology". Curr Opin Psychiatry. 19 (1): 67–73. doi:10.1097/01.yco.0000194370.40062.b0. PMID 16612182.{{cite journal}}: CS1 maint: multiple names: authors list (link)
34. Smith AK, Dimulescu I, Falkenberg VR; et al. (2008). "Genetic evaluation of the serotonergic system in chronic fatigue syndrome". Psychoneuroendocrinology. 33 (2): 188–97. doi:10.1016/j.psyneuen.2007.11.001. PMID 18079067. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
35. Chaudhuri A, Behan PO (2004). "Fatigue in neurological disorders". Lancet. 363 (9413): 978–88. doi:10.1016/S0140-6736(04)15794-2. PMID 15043967.
36. Covelli V, Passeri ME, Leogrande D, Jirillo E, Amati L (2005). "Drug targets in stress-related disorders". Curr. Med. Chem. 12 (15): 1801–9. doi:10.2174/0929867054367202. PMID 16029148.{{cite journal}}: CS1 maint: multiple names: authors list (link)
37. ^ Fukuda K, Straus S, Hickie I, Sharpe M, Dobbins J, Komaroff A (1994). "The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group". Ann Intern Med. 121 (12): 953–9. PMID 7978722.{{cite journal}}: CS1 maint: multiple names: authors list (link)
38. ^ Holmes G, Kaplan J, Gantz N, Komaroff A, Schonberger L, Straus S, Jones J, Dubois R, Cunningham-Rundles C, Pahwa S (1988). "Chronic fatigue syndrome: a working case definition,". Ann Intern Med. 108 (3): 387–9. PMID 2829679.{{cite journal}}: CS1 maint: multiple names: authors list (link) Details Cite error: The named reference "Holmes1988" was defined multiple times with different content (see the help page).
39. ^ National Institute for Health and Clinical Excellence. Guideline 53: Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy). London, 2007. ISBN 1846294533. NICE CG53 page.
40. Sharpe M, Archard L, Banatvala J, Borysiewicz L, Clare A, David A, Edwards R, Hawton K, Lambert H, Lane R (1991). "A report--chronic fatigue syndrome: guidelines for research". J R Soc Med. 84 (2): 118–21. PMID 1999813.{{cite journal}}: CS1 maint: multiple names: authors list (link) PMC 1293107 Synopsis by . GPnotebook https://www.gpnotebook.co.uk/simplepage.cfm?ID=-476446699. {{cite web}}: Missing or empty |title= (help))
41. Carruthers BM; et al. (2003). "Myalgic encephalomyalitis/chronic fatigue syndrome: Clinical working definition, diagnostic and treatment protocols" (PDF). Journal of Chronic Fatigue Syndrome. 11 (1): 7–36. doi:10.1300/J092v11n01_02. {{cite journal}}: Explicit use of et al. in: |author= (help)
42. Wearden AJ, Riste L, Dowrick C, Chew-Graham C, Bentall RP, Morriss RK, Peters S, Dunn G, Richardson G, Lovell K, Powell P (2006). "Fatigue Intervention by Nurses Evaluation - The FINE Trial. A randomised controlled trial of nurse led self-help treatment for patients in primary care with chronic fatigue syndrome: study protocol". BMC Med. 4 (9). PMID 16603058.{{cite journal}}: CS1 maint: multiple names: authors list (link)
43. Reeves WC, Lloyd A, Vernon SD, Klimas N, Jason LA, Bleijenberg G, Evengard B, White PD, Nisenbaum R, Unger ER (2003). "Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution". BMC Health Serv Res. 3 (1): 25. doi:10.1186/1472-6963-3-25. PMID 14702202.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link)
44. Jason LA, Corradi K, Torres-Harding S, Taylor RR, King C (2005). "Chronic fatigue syndrome: the need for subtypes". Neuropsychol Rev. 15 (1): 29–58. doi:10.1007/s11065-005-3588-2. PMID 15929497.{{cite journal}}: CS1 maint: multiple names: authors list (link)
45. Rimes KA, Chalder T. (2005). "Treatments for chronic fatigue syndrome". Occupational Medicine. 55 (1): 32–39. doi:10.1093/occmed/kqi015. PMID 15699088.
46. ^ [Chambers D, Bagnall AM, Hempel S, Forbes C (2006). "Interventions for the treatment, management and rehabilitation of patients with chronic fatigue syndrome/myalgic encephalomyelitis: an updated systematic review". Journal of the Royal Society of Medicine. 99 (10): 506–20. doi:10.1258/jrsm.99.10.506. PMID 17021301.{{cite journal}}: CS1 maint: multiple names: authors list (link)
47. Raine R, Haines A, Sensky T, Hutchings A, Larkin K, Black N (2002). "Systematic review of mental health interventions for patients with common somatic symptoms: can research evidence from secondary care be extrapolated to primary care?". BMJ. 325 (7372). PMID 12424170.{{cite journal}}: CS1 maint: multiple names: authors list (link)
48. ^ Whiting P, Bagnall AM, Sowden AJ, Cornell JE, Mulrow CD, Ramirez G (2001). "Interventions for the treatment and management of chronic fatigue syndrome: a systematic review". JAMA. 286 (11): 1360–8. PMID 11560542. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
49. Reid S, Chalder T, Cleare A, Hotopf M, Wessely S. (2000). "Chronic fatigue syndrome". BMJ. 320 (7230): 292–6. PMID 10650029.{{cite journal}}: CS1 maint: multiple names: authors list (link)
50. Wolfe F; Chalmers A; Littlejohn GO & Salit I (1995). Fibromyalgia, Chronic Fatigue Syndrome, and Repetitive Strain Injury: Current Concepts in Diagnosis, Management, Disability, and Health Economics. New York: Haworth Medical Press. p. 142. ISBN 1-56024-744-4.{{cite book}}: CS1 maint: multiple names: authors list (link)
51. Deary V, Chalder T, Sharpe M (2007). "The cognitive behavioural model of medically unexplained symptoms: a theoretical and empirical review". Clin Psychol Rev. 27 (7): 781–97. doi:10.1016/j.cpr.2007.07.002. PMID 17822818. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
52. ^ Price JR, Mitchell E, Tidy E, Hunot V (2008). "Cognitive behaviour therapy for chronic fatigue syndrome in adults". Cochrane Database Syst Rev (3): CD001027. doi:10.1002/14651858.CD001027.pub2. PMID 18646067.{{cite journal}}: CS1 maint: multiple names: authors list (link)
53. Deale A, Chalder T, Marks I, Wessely S (1997). "Cognitive behavior therapy for chronic fatigue syndrome: a randomized controlled trial". Am J Psychiatry. 154 (3): 408–14. PMID 9054791.{{cite journal}}: CS1 maint: multiple names: authors list (link)
54. Sharpe M, Hawton K, Simkin S, Surawy C, Hackmann A, Klimes I, Peto T, Warrell D, Seagroatt V (1996). "Cognitive behaviour therapy for the chronic fatigue syndrome: a randomized controlled trial". BMJ. 312 (7022): 22–6. PMID 8555852.{{cite journal}}: CS1 maint: multiple names: authors list (link)
55. Knoop H, Bleijenberg G, Gielissen MF, van der Meer JW, White PD (2007). "Is a full recovery possible after cognitive behavioural therapy for chronic fatigue syndrome?". Psychother Psychosom. 76 (3): 171–6. PMID 17426416.{{cite journal}}: CS1 maint: multiple names: authors list (link)
56. ^ Working Group of the Royal Australasian College of Physicians (2002). "Chronic fatigue syndrome. Clinical practice guidelines--2002". Med J Aust. 176: Suppl:S23–56. PMID 12056987. {{cite journal}}: Unknown parameter |nopp= ignored (|no-pp= suggested) (help)
57. . doi:10.1002/14651858.CD003200.pub2. {{cite journal}}: Cite journal requires |journal= (help); Missing or empty |title= (help)
58. ^ White PD, Sharpe MC, Chalder T, DeCesare JC, Walwyn R (2007). "Protocol for the PACE trial: a randomised controlled trial of adaptive pacing, cognitive behaviour therapy, and graded exercise, as supplements to standardised specialist medical care versus standardised specialist medical care alone for patients with the chronic fatigue syndrome/myalgic encephalomyelitis or encephalopathy". BMC Neurol. 7: 6. doi:10.1186/1471-2377-7-6. PMID 17397525.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link)
59. Covelli V, Passeri ME, Leogrande D, Jirillo E, Amati L (2005). "Drug targets in stress-related disorders". Curr. Med. Chem. 12 (15): 1801–9. doi:10.2174/0929867054367202. PMID 16029148.{{cite journal}}: CS1 maint: multiple names: authors list (link)
60. Cho HJ, Hotopf M, Wessely S (2005). "The placebo response in the treatment of chronic fatigue syndrome: a systematic review and meta-analysis". Psychosom Med. 67 (2): 301–13. doi:10.1097/01.psy.0000156969.76986.e0. PMID 15784798.{{cite journal}}: CS1 maint: multiple names: authors list (link)
61. Jason LA, Taylor RR, Kennedy CL (2000). "Chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities in a community-based sample of persons with chronic fatigue syndrome-like symptoms". Psychosom Med. 62 (5): 655–63. PMID 11020095.{{cite journal}}: CS1 maint: multiple names: authors list (link)
62. Clauw DJ (2001). "Potential mechanisms in chemical intolerance and related conditions". Ann. N. Y. Acad. Sci. 933: 235–53. PMID 12000024.
63. Gruber AJ, Hudson JI, Pope HG (1996). "The management of treatment-resistant depression in disorders on the interface of psychiatry and medicine. Fibromyalgia, chronic fatigue syndrome, migraine, irritable bowel syndrome, atypical facial pain, and premenstrual dysphoric disorder". Psychiatr. Clin. North Am. 19 (2): 351–69. doi:10.1016/S0193-953X(05)70292-6. PMID 8827194.{{cite journal}}: CS1 maint: multiple names: authors list (link)
64. National Center for Infectious Diseases (2005-05-11). "Treatment of Patients with Chronic Fatigue Syndrome" (htm). Centers for Disease Control and Prevention. Retrieved 2008-04-07.
65. ^ Cairns R, Hotopf M (2005). "A systematic review describing the prognosis of chronic fatigue syndrome". Occupational medicine (Oxford, England). 55 (1): 20–31. doi:10.1093/occmed/kqi013. PMID 15699087.
66. "CFS Toolkit for Health Care Professionals: Basic CFS Overview" (PDF file, 31 KB). U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Retrieved 2008-03-19. {{cite web}}: Cite has empty unknown parameter: |coauthors= (help)
67. Jason LA, Corradi K, Gress S, Williams S, Torres-Harding S (2006). "Causes of death among patients with chronic fatigue syndrome". Health care for women international. 27 (7): 615–26. doi:10.1080/07399330600803766. PMID 16844674.{{cite journal}}: CS1 maint: multiple names: authors list (link)
68. Smith WR, Noonan C, Buchwald D (2006). "Mortality in a cohort of chronically fatigued patients". Psychological medicine. 36 (9): 1301–6. doi:10.1017/S0033291706007975. PMID 16893495.{{cite journal}}: CS1 maint: multiple names: authors list (link)
69. "Fatigue syndrome ruling welcomed". 2006-06-23. Retrieved 2007-09-03.
70. Walsh CM, Zainal NZ, Middleton SJ, Paykel ES (2001). "A family history study of chronic fatigue syndrome". Psychiatr Genet. 11 (3): 123–8. doi:10.1097/00041444-200109000-00003. PMID 11702053.{{cite journal}}: CS1 maint: multiple names: authors list (link)
71. "Chronic Fatigue Syndrome Demographics" (htm). Centers for Disease Control and Prevention. May 11, 2005. Retrieved 2008-02-07.
72. Craig, T and Kakumanu S (Mar 2002). "Chronic fatigue syndrome: evaluation and treatment". Am Fam Physician. 65 (6): 1083–90. PMID 11925084.{{cite journal}}: CS1 maint: year (link)
73. Vojdani A, Thrasher J (2004). "Cellular and humoral immune abnormalities in Gulf War veterans". Environ Health Perspect. 112 (8): 840–6. doi:10.1289/ehp.6881. PMID 15175170.
74. Bruno RL, Creange SJ, Frick NM (1998). "Parallels between post-polio fatigue and chronic fatigue syndrome: a common pathophysiology?". Am J Med. 105 (3A): 66S–73S. doi:10.1016/S0002-9343(98)00161-2. PMID 9790485.{{cite journal}}: CS1 maint: multiple names: authors list (link)
75. Gaudino EA, Coyle PK, Krupp LB (1997). "Post-Lyme syndrome and chronic fatigue syndrome. Neuropsychiatric similarities and differences". Arch Neurol. 54 (11): 1372–6. PMID 9362985.{{cite journal}}: CS1 maint: multiple names: authors list (link)
76. van Staden WC (2006). "Conceptual issues in undifferentiated somatoform disorder and chronic fatigue syndrome". Curr Opin Psychiatry. 19 (6): 613–8. PMID 17012941.
77. Jenkins R, Mowbray J, ed. Post-viral Fatigue Syndrome. 1991 John Wiley & Sons Ltd
78. Frank RG, Chaney JM, Clay DL, Shutty MS, Beck NC, Kay DR, Elliott TR, Grambling S (1992). "Dysphoria: a major symptom factor in persons with disability or chronic illness". Psychiatry Res. 43 (3): 231–41. doi:10.1016/0165-1781(92)90056-9. PMID 1438622.{{cite journal}}: CS1 maint: multiple names: authors list (link)
79. Bradley LA, McKendree-Smith NL, Alarcon GS (2000). "Pain complaints in patients with fibromyalgia versus chronic fatigue syndrome". Curr Rev Pain. 4 (2): 148–57. PMID 10998728.{{cite journal}}: CS1 maint: multiple names: authors list (link)
80. Friedberg F, Jason LA (2001). "Chronic fatigue syndrome and fibromyalgia: clinical assessment and treatment". J Clin Psychol. 57 (4): 433–55. doi:10.1002/jclp.1040. PMID 11255201.
81. Pall ML, Satterlee JD (2001). "Elevated nitric oxide/peroxynitrite mechanism for the common etiology of multiple chemical sensitivity, chronic fatigue syndrome, and posttraumatic stress disorder". Ann N Y Acad Sci. 933: 323–9. PMID 12000033.
82. Aaron LA, Herrell R, Ashton S, Belcourt M, Schmaling K, Goldberg J, Buchwald D (2001). "Comorbid clinical conditions in chronic fatigue: a co-twin control study". J Gen Intern Med. 16 (1): 24–31. doi:10.1111/j.1525-1497.2001.03419.x. PMID 11251747.{{cite journal}}: CS1 maint: multiple names: authors list (link)
83. Sinaii N, Cleary SD, Ballweg ML, Nieman LK, Stratton P (2002). "High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis: a survey analysis". Hum Reprod. 17 (10): 2715–24. doi:10.1093/humrep/17.10.2715. PMID 12351553.{{cite journal}}: CS1 maint: multiple names: authors list (link)
84. Patarca-Montero R (2004). Medical Etiology, Assessment, and Treatment of Chronic Fatigue and Malaise. Haworth Press. pp. 6–7. ISBN 078902196X.
85. "AN OUTBREAK of encephalomyelitis in the Royal Free Hospital Group, London, in 1955". Br Med J. 2 (5050): 895–904. 1957. PMID 13472002.
86. International Classification of Diseases, vol. I, World Health Organization, 1969, pp. 158, (vol 2, pp. 173)
87. Sharpe M & Campling F (2000). Chronic Fatigue Syndrome (CFS/ME): TheFacts. Oxford: Oxford Press. pp. 14, 15. ISBN 0-19-263049-0. Retrieved 2008-04-02.
88. Packard RM, Berkelman RL, Brown PJ, Frumkin H (2004). Emerging Illnesses and Society. JHU Press. p. 156. ISBN 0801879426. Retrieved 2008-04-02.{{cite book}}: CS1 maint: multiple names: authors list (link)
89. Rogers, Richard (1997). Clinical Assessment of Malingering and Deception, Second Edition. New York, London: Guilford Press. p. 40. ISBN 1572301732. {{cite book}}: More than one of |pages= and |page= specified (help)
90. Malleson, Andrew (2005). Whiplash and Other Useful Illnesses. Quebec: McGill-Queen's Press. pp. g 59 of 544. ISBN 0773529942.
91. Van Houdenhove B, Neerinckx E, Onghena P, Vingerhoets A, Lysens R, Vertommen H (2002). "Daily hassles reported by chronic fatigue syndrome and fibromyalgia patients in tertiary care: a controlled quantitative and qualitative study". Psychother Psychosom. 71 (4): 207–13. doi:10.1159/000063646. PMID 12097786.{{cite journal}}: CS1 maint: multiple names: authors list (link)
92. Action for M.E. in the UK, Severely Neglected: Membership Survey London: Action for M.E.; 2001
93. Prins JB, Bos E, Huibers MJ, Servaes P, van der Werf SP, van der Meer JW, Bleijenberg G (2004). "Social support and the persistence of complaints in chronic fatigue syndrome". Psychother Psychosom. 73 (3): 174–82. doi:10.1159/000076455. PMID 15031590.{{cite journal}}: CS1 maint: multiple names: authors list (link)
94. Colby J (2007). "Special problems of children with myalgic encephalomyelitis/chronic fatigue syndrome and the enteroviral link". J Clin Pathol. 60 (2): 125–8. doi:10.1136/jcp.2006.042606. PMID 16935964. 16935964.
95. Looper KJ, Kirmayer LJ (2004). "Perceived stigma in functional somatic syndromes and comparable medical conditions". J Psychosom Res. 57 (4): 373–8. PMID 15518673.
96. Clarke JN (1999). "Chronic fatigue syndrome: gender differences in the search for legitimacy". Aust N Z J Ment Health Nurs. 8 (4): 123–33. doi:10.1046/j.1440-0979.1999.00145.x. PMID 10855087.
97. Jason L, Corradi K, Gress S, Williams S, Torres-Harding S (2006). "Causes of death among patients with chronic fatigue syndrome". Health Care Women Int. 27 (7): 615–26. doi:10.1080/07399330600803766. PMID 16844674.{{cite journal}}: CS1 maint: multiple names: authors list (link)
98. Wallace, PG (1991). "Post-viral fatigue syndrome. Epidemiology: a critical review". Br Med Bull. 47 (4): 942–951. PMID 1794092. {{cite journal}}: Unknown parameter |month= ignored (help)
99. ^ Mounstephen, A, (1997). "Chronic fatigue syndrome and occupational health". Occup Med (Lond). May;47(4):. 47 (4): 217–227. doi:10.1093/occmed/47.4.217. PMID 1794092. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)CS1 maint: extra punctuation (link) CS1 maint: multiple names: authors list (link)
100. Hooge J (1992). "Chronic fatigue syndrome: cause, controversy and care". Br J Nurs. 1 (9): 440–1, 443, 445–6. PMID 1446147.
101. Sharpe M (1996). "Chronic fatigue syndrome". Psychiatr. Clin. North Am. 19 (3): 549–73. doi:10.1016/S0193-953X(05)70305-1. PMID 8856816.
102. Denz-Penhey H, Murdoch JC (1993). "General practitioners acceptance of the validity of chronic fatigue syndrome as a diagnosis". N. Z. Med. J. 106 (953): 122–4. PMID 8474729.
103. Greenlee JE, Rose JW (2000). "Controversies in neurological infectious diseases". Semin Neurol. 20 (3): 375–86. doi:10.1055/s-2000-9429. PMID 11051301.
104. ^ Horton-Salway M (2007). "The ME Bandwagon and other labels: constructing the genuine case in talk about a controversial illness". Br J Soc Psychol. 46 (Pt 4): 895–914. doi:10.1348/014466607X173456. PMID 17535450.
105. Engel CC, Adkins JA, Cowan DN (2002). "Caring for medically unexplained physical symptoms after toxic environmental exposures: effects of contested causation". Environ. Health Perspect. 110 Suppl 4: 641–7. PMID 12194900.{{cite journal}}: CS1 maint: multiple names: authors list (link)
106. Dumit, J. (2005-08-08). "Illnesses you have to fight to get: facts as forces in uncertain, emergent illnesses". Soc Sci Med. Feb, 62 (3): 577–90. PMID 16085344.
107. NORD (June 23, 2008). "Chronic Fatigue Syndrome/Myalgic Encephalomyelitis" (html). National Organization for Rare Disorders, Inc. Retrieved 2008-07-01.
108. Donoghue, PJ (1992). Sick And Tired Of Feeling Sick And Tired: Living with Invisible Chronic Illness. W. W. Norton & Company. p. 15. ISBN 0393034089. Retrieved 2008-09-17. {{cite book}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
109. "About CFIDS". CFIDS Association of America. Retrieved 2008-10-23.
110. Sharpe M (2002). "The report of the Chief Medical Officer's CFS/ME working group: what does it say and will it help?". Clin Med. 2 (5): 427–9. PMID 12448589.
111. Tuller, D (2007-07-17). "Chronic Fatigue Syndrome No Longer Seen as "Yuppie Flu"". The New York Times. {{cite news}}: |access-date= requires |url= (help)
112. ^ Evangard B, Schacterie R.S., Komaroff A. L. (1999). "Chronic fatigue syndrome: new insights and old ignorance". Journal of Internal Medicine. Nov, 246 (5): 455–469. PMID 10583715. Retrieved 2008-11-03.{{cite journal}}: CS1 maint: multiple names: authors list (link)
113. "The Psychiatry Research Trust - Chronic Fatigue Syndrome". Retrieved 2008-11-30.
114. Clark C, Buchwald D, MacIntyre A, Sharpe M, Wessely S (2002). "Chronic fatigue syndrome: a step towards agreement". Lancet. 359 (9301): 97–8. PMID 11809249. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)

External links

• Chronic Fatigue Syndrome at the US Centers for Disease Control and Prevention
• Template:DMOZ

• Immune system disorders
• Neurological disorders
• Ailments of unknown etiology
• Syndromes
• Chronic illness